Omeprazole-induced calcium pyrophosphate disease: case report (Eng)
Article Sidebar
Main Article Content
Abstract
Calcium pyrophosphate disease is caused by the accumulation of calcium pyrophosphate crystals in cartilage, causing acute intermittent arthritis or chronic arthritis. Risk factors for calcium pyrophosphate disease include old age. Osteoarthritis is the most common comorbidity. Other risk factors include local joint injury, primary hyperparathyroidism, hereditary hemochromatosis, hypomagnesemia (for example, due to intestinal problems), diseases caused by loss of magnesium in the kidneys (especially Gitelman syndrome), familial hypocalcemia, hypophosphatemia, and hereditary calcium pyrophosphate disease. There is evidence that proton pump inhibitors are a clear risk factor for calcium pyrophosphate syndrome. There have been reports of acute tubulointerstitial nephritis, proximal renal tubular cell death and chronic kidney disease. But there has been only one case report of calcium pyrophosphate disease associated with the use of proton pump inhibitor. I therefore report on a case of an 82-year-old Thai woman with pseudogouty arthritis and has hypomagnesemia, kidney impairment, proximal renal tubular cell death and uses omeprazole for more than 10 years. When omeprazole was stopped and hypomagnesemia was corrected, it was found that the kidneys were better. There was no more arthritis after 1 year of follow-up.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
(ใส่ข้อความเดียวกันกับ ก๊อปปี้ไลน์ก็ได้)ดูตัวอย่างได้ที่หน้าบทความ---บทความนี้ตีพิมพ์เป็นลิขสิทธื์ของใคร...
References
Abhishek A, Neogi T, Choi H, et al. Unmet needs and the path forward in joint disease associated with calcium pyrophosphate crystal deposition. Arthritis Rheumatol 2018;70:1182-91.
Rosenthal AK, Ryan LM. Calcium pyrophosphate deposition disease. N Engl J Med 2016; 374:2575-84.
Latourte A, Ea HK, Richette P. Calcium pyrophosphate and basic calcium phosphate crystal arthritis: 2023 in review Gout Urate Cryst Depos Dis 2024; 2:101-7.
Abhishek A, Tedeschi SK, Pascart T, et al. The 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease. Ann Rheum Dis 2023; 82:1248-57
Adinolfi A, Sirotti S, Sakellariou G, et al. Which are the most frequently involved peripheral joints in calcium pyrophosphate crystal deposition at imaging? A systematic literature review and meta-analysis by the OMERACT ultrasound—CPPD subgroup Front Med (Lausanne) 2023;10,1131362
McCarthy DJ, Hollander JL. Arthritis and allied conditions: a textbook of rheumatology Lea & Febiger, Philadelphia, PA, 1966; 947-64.
Abhishek A, Doherty S, Maciewicz RA, et al. Self-reported knee malalignment in early adult life as an independent risk for knee chondrocalcinosis. Arthritis Care Res (Hoboken) 2011; 63:1550-7
Doherty M, Watt I, Dieppe PA. Localised chondrocalcinosis in post-meniscectomy knees Lancet 1982;1:1207-10
Abhishek A, Doherty M. Epidemiology of calcium pyrophosphate crystal arthritis and basic calcium phosphate crystal arthropathy. Rheum Dis Clin North Am 2014;40:177-91
Neame RL, Carr AJ, Muir K, et al. UK community prevalence of knee chondrocalcinosis: evidence that correlation with osteoarthritis is through a shared association with osteophyte
Ann Rheum Dis 2003; 62:513-8.
Jones AC, Chuck AJ, Arie EA, et al. Diseases associated with calcium pyrophosphate deposition disease. Semin Arthritis Rheum 1992;22:188-202
Volpe A, Guerriero A, Marchetta A. Familial hypocalciuric hypercalcemia revealed by chondrocalcinosis. Joint Bone Spine 2009; 76:708-10.
Richette P, Ayoub G, Lahalle S.Hypomagnesemia associated with chondrocalcinosis: a cross-sectional study. Arthritis Rheum 2007;57:1496-501.
Chotard E, Blanchard A, Ostertag A. Calcium pyrophosphate crystal deposition in a cohort of 57 patients with Gitelman syndrome. Rheumatology (Oxf) 2022;61:2494-503.
Mouly C, Vargas-Poussou R, Lienhardt A. Clinical characteristics of familial hypocalciuric hypercalcaemia type 1: a multicentre study of 77 adult patients Clin Endocrinol (Oxf) 2020;93:248-60.
Abhishek A, Doherty M. Pathophysiology of articular chondrocalcinosis—role of ANKH Nat Rev Rheumatol 2011;7:96-104.
Williams CJ, Qazi U, Bernstein M, et al. Mutations in osteoprotegerin account for the CCAL1 locus in calcium pyrophosphate deposition disease. Osteoarthritis Cartilage 2018;26:797-806.
Liew JW, Peloquin C, Tedeschi SK, et al. Proton-pump inhibitors and risk of calcium pyrophosphate deposition in a population-based study Arthritis Care Res (Hoboken) 2022; 74:2059-65.
Brewster UC, Perazella MA. Proton pump inhibitors and the kidney: critical review. Clin Nephrol 2007;68:65-72.
Bellomo R, Kellum JA, Ronco C. Acute kidney injury. Lancet 2012;380(9843):756–766.
Torlot FJ, Whitehead DJ. Acute interstitial nephritis caused by two different proton pump inhibitors. Br J Hosp Med (Lond) 2016;77:50–1.
Ni N, Moeckel GW, Kumar C. Late-onset omeprazole-associated acute interstitial nephritis. J Am Geriatr Soc 2010;58(12):2443–4.
Brewster UC, Perazella MA. Acute kidney injury following proton pump inhibitor therapy. Kidney Int 2007;71:589–93.
Muriithi AK, Leung N, Valeri AM, Cornell LD, Sethi S, Fidler ME. Clinical characteristics, causes and outcomes of acute interstitial nephritis in the elderly. Kidney Int 2015;87(2):458–64.
Nadri Q, Althaf MM. Granulomatous tubulointerstitial nephritis secondary to omeprazole. BMJ Case Rep 2014;2014 doi: 10.1136/bcr-2014-203842.
Fontecha-Barriuso M, Martín-Sanchez D, Martinez-Moreno JM, Cardenas-Villacres D, Carrascoc S, Sanchez-Niño MD, et al. Molecular pathways driving omeprazole nephrotoxicity. Redox Biol 2020 Feb 12;32:101464. doi: 10.1016/j.redox.2020.101464.
Epstein M, McGrath S, Law F. Proton-pump inhibitors and hypomagnesemia hypoparathyroidism. N Engl J Med 2006;355:1834-6.
Cundy T, MacKay J. Proton pump inhibitors and severe hypomagnesemia. Curr Opin Gastroenterol 2011;27:180-5.
Mark A. Proton pump inhibitors and hypomagnesemia: a rare but serious complication. Kidney Int 2013;83:553-6.
Kieboom BC, Kiefte de Jong JC, Eijgelsheim M, et al. Proton pump inhibitors and hypomagnesemia in the general population: a population based cohort study. Am J Kidney Dis 2015;66(5):775-2.
Zipursky J, Macdonald EM, Hollands S, et al. Proton pump inhibitors and hospitalization with hypomagnesemia: a population based case control study. PLoS Med 2014;11(9):e1001736. doi:org/10.1371/journal.pmed.1001736
Cundy T, Dissanayake A. Severe hypomagnesaemia in long term users of proton pump inhibitors. Clin Endocrinol (Oxf) 2008;69:338-41.
de Baaij JH, Hoenderop JG, Bindels RJ. Magnesium in man: implications for health and disease. Physiol Rev 2015;95:1-46.
Liew JW, Peloquin C, Tedeschi SK, Felson DT, Zhang Y, Choi HK, et al. Proton-Pump Inhibitors and Risk of Calcium Pyrophosphate Deposition in a Population-Based Study. Arthritis care & Research 2022;74:2059-65.
Neogi T, Peloquin C, Terkeltaub R, Felson D. Use of proton pump inhibitors increases the risk of calcium pyrophosphate deposition (CPPD) in a population-based study. European crystal network workshop 2025 https://www.european-crystal-network.com/ecn_librairie_resume.php?id=YJP08hIAACQAitsH
Kasuma N. Correlation between magnesium and alkaline phosphatase from gingival crevicular fluid on periodontal diseases. Dent J 2015;48:130-4.
Joshi A, Siva C. Magnesium disorders can cause calcium pyrophosphate deposition disease: a case report and literature review. Eur J Rheumatol 2018;5:53–7.
Challita R, Azar L. A 65-Year-Old Man With a Curious Cause of Chronic Arthritis “Hiding in the Pill Box. Arthritis Care Res 2024;76:1355–60.
Tedeschi SK, Yoshida K, Huang W, Solomon DH. Confirming Prior and Identifying Novel Correlates of Acute Calcium Pyrophosphate Crystal Arthritis. Arthritis Care Res (Hoboken) 2022 Sep 15;75(2):283–288.
